louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07018011: Comparison of Conventional Versus Transverse Mini-Incision Technique for Carpal Tunnel Release
Official title: Comparison of Conventional Versus Transverse Mini-Incision Technique for Carpal Tunnel Release: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Lead sponsor: RESnTEC, Institute of Research
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed at to fill the gaps by comparing the surgical outcomes of the conventional versus transverse mini-incision technique for carpal tunnel syndrome in terms of pain and functional outcomes.

Detailed description: The study findings would be helpful in determining the superiority of one surgical technique over the other for carpal tunnel release so that a quicker return to normal activities and work for those patients could be achieved, causing less pain and scarring. Due to frequent healthcare visits, quality of life can also be improved along with a decrease in morbidity.

Eligibility criteria: Inclusion Criteria:

* Any genders
* Aged between 18 and 70 years
* Presenting with symptoms of carpal tunnel syndrome for at least 3 months duration, and having a VAS score \> 4.

Exclusion Criteria:

* Patients with wrists with thenar atrophy
* Those who had previous CTR surgery
* Local injection for CTS
* Pregnant females
* Patients suffering from inflammatory arthropathy
* Polyneuropathy

Primary outcomes:
measure: Pain severity
timeFrame: 9 months
measure: Functional outcome
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sahiwal
country: Pakistan
facility: Sahiwal Teaching Hospital
state: Punjab
Study officials:
affiliation: Sahiwal Teaching Hospital, Sahiwal
name: Kashif Raza, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Sahiwal Teaching Hospital, Sahiwal
name: Muhammad Rashid, FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02938611: Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France
Official title: Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Renal Insufficiency, Chronic
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2016-10-19
Enrollment: 3375
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Persons with \>= stage 4 chronic kidney disease and residing in the Gard department of France.

Brief summary: The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.


Eligibility criteria: Inclusion Criteria:

* chronic kidney disease (stage \>= 4)

Exclusion Criteria:

-

Primary outcomes:
measure: The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
timeFrame: from baseline (day 0) to 12 months
measure: The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
timeFrame: from baseline (day 0) to 12 months
Secondary outcomes:
measure: The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
timeFrame: from baseline (day 0) to 12 months
measure: For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
timeFrame: from baseline (day 0) to 12 months
measure: The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
timeFrame: from baseline (day 0) to 12 months
Other outcomes:
Locations:
city: Alès
country: France
facility: AIDER - Unité de Dialyse d'Alès
city: Nîmes Cedex 09
country: France
facility: AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémeau
city: Nîmes
country: France
facility: Gardialyse
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: Olivier Moranne, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03957928: Effects of Fresh Mango Pulp Consumption on Satiety and Cardiometabolic Health
Official title: Effects of Fresh Mango Pulp Consumption on Satiety and Cardiometabolic Health
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Satiety
Lead sponsor: San Diego State University
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The objective of the study is to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults.


Eligibility criteria: Inclusion Criteria:

* 18-55 years old
* BMI 27-40

Exclusion Criteria:

* Smoker
* Pregnant woman
* Required dietary supplement use
* Required medication of metabolic disorders
* Allergy to mango or gluten

Primary outcomes:
measure: Change of satiety
timeFrame: 0, 20, 40, 60, 90 and 120 minutes post snack consumption
measure: Change of glucose level
timeFrame: 0, 30, 60, 90 and 120 minutes post snack consumption; baseline and week 12
measure: Change of insulin level
timeFrame: 0 and 60 minutes post snack consumption, baseline and week 12
Secondary outcomes:
measure: Change of microbiome
timeFrame: Baseline, week 4 and week12
Other outcomes:
Locations:
city: San Diego
country: United States
facility: School of Exercise and Nutritional Sciences, SDSU
state: California
Study officials:
References:
citation: Rosas M Jr, Pinneo S, O'Mealy C, Tsang M, Liu C, Kern M, Hooshmand S, Hong MY. Effects of fresh mango consumption on cardiometabolic risk factors in overweight and obese adults. Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):494-503. doi: 10.1016/j.numecd.2021.11.001. Epub 2021 Nov 12.
citation: Pinneo S, O'Mealy C, Rosas M Jr, Tsang M, Liu C, Kern M, Hooshmand S, Hong MY. Fresh Mango Consumption Promotes Greater Satiety and Improves Postprandial Glucose and Insulin Responses in Healthy Overweight and Obese Adults. J Med Food. 2022 Apr;25(4):381-388. doi: 10.1089/jmf.2021.0063. Epub 2021 Nov 23.
Clinical trial NCT00496028: Phase I Study in Patients With Solid Tumours
Official title: A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neoplasms
Keywords: Solid tumors
locally advanced or Metastatic Cancer suitable for treatment with carboplatin and/or paclitaxel
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-07-04
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.


Eligibility criteria: Inclusion Criteria:

* Life expectancy \> 12 weeks
* Women defined as post-menopausal
* Male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel

Exclusion Criteria:

* Inadequate bone marrow reserve
* Inadequate live function, renal function or low haemoglobin
* Unresolved toxicity from anti-cancer therapy

Primary outcomes:
measure: To evaluate the safety and tolerability of AZD0530 in combination with carboplatin and/or paclitaxel regimens with solid tumours by assessment of AEs, physical examination, BP, pulse, ECG, laboratory findings, PFTs and thoracic CT scans.
timeFrame: Assessed at each visit
Secondary outcomes:
measure: To determine the Maximum Tolerated Dose of AZD0530 when administered in combination with carboplatin and/or paclitaxel by assessment of safety and tolerability data generated for each treatment arm.
timeFrame: Assessed at each visit
measure: To make a preliminary evaluation of clinical response by assessment of RECIST evaluation, time to progression and serum tumour markers.
timeFrame: Assessment at end of study
measure: To investigate the PK of AZD0530. paclitaxel and carboplatin when co-administered to patients with solid tumours, by assessment of appropriate PK parameters.
timeFrame: Predetermined timepoints after dose administration
Other outcomes:
Locations:
city: Paris
country: France
facility: Research Site
city: Pierre Benite Cedex
country: France
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
city: Groningen
country: Netherlands
facility: Research Site
city: Oslo
country: Norway
facility: Research Site
city: Glasgow
country: United Kingdom
facility: Research Site
city: Sutton
country: United Kingdom
facility: Research Site
Study officials:
affiliation: Radium Hospital, Norway
name: Steinar Aamdal, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca
name: Mary Stuart, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02726828: intrathecaم Ketamine, Morphine and Both for Lower Abdominal Cancer Surgery Pain
Official title: Effects of Intrathecally Administered Ketamine, Morphine and Their Combination in Patients Undergoing Major Abdominal Cancer Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Postoperative Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2016-04-04
Enrollment: 90
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: this study investigates the analgesic efficacy and other possible effects of ketamine, morphine, and both together when administered intrathecally for control of postoperative pain following lower abdominal cancer surgeries.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesia (ASA) I-III patients.
* aged 30-50 years.
* scheduled for major abdominal cancer surgery.

Exclusion Criteria:

* Patients with a known allergy to the study drugs.
* significant cardiac, respiratory, renal or hepatic disease.
* coagulation disorders.
* infection at or near the site of intrathecal injection.
* drug or alcohol abuse.
* BMI \> 30 kg/m2.
* psychiatric illnesses that may interfere with perception and assessment of pain.

Primary outcomes:
measure: Visual Analogue Scale (VAS) scores
timeFrame: 24 hours postoperative
measure: time to first analgesic request
timeFrame: 24 hours postoperative
measure: total analgesic consumption
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: side effects
timeFrame: 24 hours postoperative
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00897728: Study of Tumor and Blood Samples From Women With Breast Cancer
Official title: Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: stage IA breast cancer
stage IB breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
HER2-positive breast cancer
triple-negative breast cancer
estrogen receptor-negative breast cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2009-05-12
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at tumor and blood samples from women with breast cancer.

Detailed description: OBJECTIVES:

Primary

* Assess relapse locally or remotely using biomarkers collected from primary tumor and blood samples from women with breast cancer during the first 2 years after diagnosis.

Secondary

* Evaluate all relapses.
* Assess survival without relapse.
* Determine correlation between biomarkers and relapse.

OUTLINE: Primary tumor and blood samples collected during usual care of patients during the first 2 years after diagnosis are analyzed for biomarkers useful in monitoring and diagnosing breast cancer.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Diagnosis of infiltrating unilateral breast cancer

  * No in situ disease (ductal or lobular)
  * No invasive bilateral synchronous disease
* Breast cancer at high risk, defined by at least 2 of the following factors:

  * Hormone receptor negative (HR-)
  * Axillary node positive
  * Histopathologic grade III
  * High mitotic index (as defined by the Curie Institute as \> 20 mitoses per 10 high-power fields \[HPF\])
  * Tumor size ≥ 2 cm
  * HER2-positive (3 + IHC or FISH/ICHS positive)
  * Triple-negative tumors (HR- and HER2-negative)
* Initial thoracic-abdomino-pelvic and bone scans must be negative
* Underwent initial surgery

PATIENT CHARACTERISTICS:

* Menopausal status not specified
* Serum calcium normal (15.3 mg/dL) or normalized within 8 weeks after surgery
* No other invasive cancer within the past 5 years
* Not pregnant or nursing
* No psychological, familial, social, or geographical reasons that make monitoring impossible

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Primary outcomes:
measure: Local or remote relapse as assessed by biomarkers in tissue and blood samples collected during the first 2 years after diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut Curie Hopital
Study officials:
affiliation: Institut Curie
name: Paul-Henri Cottu
role: STUDY_CHAIR
References:
Clinical trial NCT05408728: Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome
Official title: Dietary Sugar Hyper-absorptive Intestinal Phenotype as a Predictor of Weight Loss Post-bariatric Surgery
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Obese
Healthy
Bariatric Surgery Candidate
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-06-07
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese patients scheduled for bariatric surgery (BS) (both men and women of any racial/ethnic background), or lean BS-naïve subjects presenting for surveillance/screening endoscopy procedure as part of their standard medical care (controls).

Brief summary: This study is trying to determine whether the success of bariatric surgery can be predicted by evaluating the dietary sugar absorptive characteristics in the small intestine and if there is any gene expression change on the dietary sugar absorptive characteristics.


Eligibility criteria: Inclusion Criteria:

- Obese patients (BMI ≥ 30) scheduled for BS undergoing standard of care screening EGD, or lean BS-naïve individuals (BMI ≤ 25) subjected to EGD for routine clinical indications as part of standard care.

Exclusion Criteria:

* Adults unable to consent, including non-English speakers.
* Pregnant women because endoscopy is a risk factor. All patients of childbearing age undergo history as well as urine pregnancy test as a standard of care prior to undergoing endoscopy as the procedure is performed under anesthesia.
* Prisoners.
* Subjects with preexisting conditions (e.g., bleeding at the time of the procedure, suspected perforation during the standard-of-care procedure) will be excluded from the study at the time of the endoscopy.
* Have a contraindication to endoscopy.
* A history of surgery on the stomach or small intestine.
* Type 1 diabetes (clinical diagnosis and/or positive glutamic acid decarboxylase antibodies).
* Using weight loss medications.
* Active malignancy within the last 5 years.

Primary outcomes:
measure: Number of obese patients with altered dietary sugar hyper-absorptive phenotype after bariatric surgery
timeFrame: 18 months
Secondary outcomes:
measure: Epigenetic changes measured in the intestinal mucosa of obese patients with dietary sugar hyper-absorptive phenotype after bariatric surgery
timeFrame: 18 months
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Dilhana Badurdeen, MBBS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06907628: A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Official title: A Phase Ⅰ, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-3792 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-04-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.


Eligibility criteria: Inclusion Criteria:

1. Subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study.
2. Patients with unresectable recurrent or metastatic solid tumors.
3. There is at least one lesion that could be measured.
4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
5. Adequate organ functions as defined.
6. Life expectancy ≥ 3 months.

Exclusion Criteria:

1. Patients with known active central nervous system (CNS) metastases.
2. Subjects with other malignancy in five years before the first dose.
3. Patients with tumor-related pain that cannot be controlled as determined.
4. Patients with serious cardiovascular and cerebrovascular diseases.
5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion.
6. Patients with severe infections.
7. History of immunodeficiency.
8. History of autoimmune diseases.
9. Active infection.
10. Pregnant or nursing women.
11. Known history of serious allergic reactions to the investigational product or its main ingredients.

Primary outcomes:
measure: Maximum tolerated dose (MTD)
timeFrame: From the first dose of study medication up to 21 days.
measure: Recommended phase Ⅱ dose (RP2D)
timeFrame: From the first dose of study medication up to 21 days.
measure: Incidence of dose limited toxicity (DLT)
timeFrame: From the first dose of study medication up to 21 days.
measure: Adverse events (AEs)
timeFrame: Up to 24 weeks.
measure: Serious adverse events (SAEs)
timeFrame: Up to 24 weeks.
Secondary outcomes:
measure: Objective response rate (ORR)
timeFrame: Up to 6 months.
Other outcomes:
Locations:
city: Jinan
country: China
facility: Shandong First Medical University Affiliated Cancer Hospital
state: Shandong
Study officials:
References:
Clinical trial NCT02033928: Comprehensive Frailty Assessment
Official title: Comprehensive Frailty Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myeloma, Multiple
Paraproteinemias
Hematologic Neoplasms
Keywords: Myeloma
MGUS (monoclonal gammopathy of undetermined significance)
amyloidosis
stem cell transplant
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2014-01-13
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients at The Ohio State University with a plamsa cell dyscrasia and/or any patient receiving a blood or marrow transplant at Ohio State will be considered for this study.

Brief summary: The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".


Eligibility criteria: Inclusion Criteria:

* patients with a plasma cell dyscrasia AND/OR any patient receiving a stem cell transplant for a hematologic malignancy at The Ohio State University
* at least 18 years of age

Exclusion Criteria:

- Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.

Primary outcomes:
measure: Change in Comprehensive Frailty Assessment
timeFrame: up to 14 months
Secondary outcomes:
measure: Time to progression
timeFrame: date of enrollment to date of documented clinical progression up to two years post-enrollment
Other outcomes:
measure: Overall survival
timeFrame: enrollment to date of death up to two years post-enrollment
Locations:
city: Columbus
country: United States
facility: The Ohio State University Hospital East
state: Ohio
Study officials:
affiliation: The Ohio State University Comprehensive Cancer Center
name: Ashley Rosko, MD
role: PRINCIPAL_INVESTIGATOR
References: